肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2013 ASCO-CAP指南：关于乳腺癌人表皮生长因子受体2检测的建议（更新版）

2013-10-07 美国病理学家协会 JCO.Oct,7

ASCO乳腺癌

中文标题：

2013 ASCO-CAP指南：关于乳腺癌人表皮生长因子受体2检测的建议（更新版）

英文标题：

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

发布机构：

美国病理学家协会

发布日期：

2013-10-07

简要介绍：

2013年10月7日，美国临床肿瘤学会(ASCO)与美国病理学家协会(CAP)共同发布了2013年的《关于乳腺癌人表皮生长因子受体2检测的建议指南》，该版本是2007年的更新版！

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207556, encodeId=6ac3120e55634, content=厉害厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:23 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207555, encodeId=9a5f120e55573, content=不错哦，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:04:28 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954541, encodeId=9a6c954541e5, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 13:40:52 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2022-03-31 ms2000001047258750

    厉害厉害

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207556, encodeId=6ac3120e55634, content=厉害厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:23 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207555, encodeId=9a5f120e55573, content=不错哦，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:04:28 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954541, encodeId=9a6c954541e5, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 13:40:52 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2022-03-31 ms2000001047258750

    不错哦，很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207556, encodeId=6ac3120e55634, content=厉害厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:23 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207555, encodeId=9a5f120e55573, content=不错哦，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:04:28 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954541, encodeId=9a6c954541e5, content=资料好好，但无法分享，遗憾！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 13:40:52 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好，但无法分享，遗憾！

    0

相关指南

ASCO指南：应用药物降低乳腺癌风险

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2013-07-08

2013 ASCO指南：肿瘤病人保留生育能力指南（更新版）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2013-05-28

2013 ASCO指南：癌症患者静脉血栓栓塞症的预防和治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2013-05-13

ASCO2013：癌症患者的中央静脉导管护理

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2013-03-04

2013 ASCO:成人恶性肿瘤中性粒细胞减少伴发热抗菌药物预防和门诊管理临床指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2013-01-08

2012ASCO指南：乳腺癌生存者随访诊疗指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2012-11-05